It was quite a strange year for our top pharmas. A top 10 company spun off its innovative pharma unit, the biggest acquisition came from a company at the bottom of our list (Gilead's $11 billion purchase of Pharmasset and its hepatitis C pipeline), and the biggest launch came from a company that's not even in the Top 20: Vertex, which posted almost $1 billion in revenues in seven months for HCV treatment Incivek.
The ranks were relatively stable, with minor shifts based on acquisition integrations. More often, exchange rate fluctuations tweaked the results a bit, boosting companies that would otherwise look anemic or worse. The euro and krone both rose 5%, the British pound was up 4%, the yen was up 9%, and the Swiss franc blew up 18%.
For USD-reporting companies, total revenues rose 6% to $301.5 billion. The days of double-digits are long gone . . .
—Gil Y. Roth
Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe
All profiles written by Gil Roth, except Astellas and Daiichi-Sankyo, by Kristin Brooks
The Lowe Down capsules written by Derek Lowe (http://pipeline.corante.com)
Pipeline information compiled by Kristin Brooks
Revenue information compiled by Gil Roth
Photo courtesy of Eli Lilly & Co.
Top 20 Pharmaceutical Companies
based on 2011 pharma revenues
Note: In all Top Company profiles, dollar amounts are in millions.